Minimally invasive esophagectomy for cancer in COVID hospitals and oncological hubs: are the outcomes different?

IF 0.6 4区医学 Q4 SURGERY

European Surgery-Acta Chirurgica Austriaca Pub Date : 2022-01-01 Epub Date: 2022-03-18 DOI:10.1007/s10353-022-00751-1

Pamela Milito, Emanuele Asti, Marco Resta, Luigi Bonavina

{"title":"Minimally invasive esophagectomy for cancer in COVID hospitals and oncological hubs: are the outcomes different?","authors":"Pamela Milito, Emanuele Asti, Marco Resta, Luigi Bonavina","doi":"10.1007/s10353-022-00751-1","DOIUrl":null,"url":null,"abstract":"Introduction: The outbreak of coronavirus disease 2019 (COVID-19) has caused significant delays in oncological care worldwide due to restriction of elective surgery and intensive care unit capacity. It has been hypothesized that COVID-free oncological hubs can provide safer elective cancer surgery compared to COVID hospitals. The primary aim of the present study was to analyze the outcomes of minimally invasive esophagectomy for cancer performed in both hospital settings by the same surgical staff.Methods: All esophagectomies for cancer performed during the pandemic by a single team were reviewed and data were compared with control patients operated during the preceding year. Screening for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) was performed prior to surgery, and special precautions were taken to mitigate hospital-related transmission of COVID-19 among patients and healthcare workers.Results: Compared to the prepandemic period, the esophagectomy volume decreased by 64%. Comorbidities, time from onset of symptoms to first visit, waiting time between diagnosis and surgery, operative approach and technique, and the pathological staging were similar. None of the patients tested positive for COVID-19 during in-hospital stay, and esophagectomy was associated with similar outcomes compared to control patients.Conclusion: Outcomes of minimally invasive esophagectomy for cancer performed in a COVID hospital after implementation of a COVID-free surgical pathway did not differ from those obtained in an oncological hub by the same surgical team.","PeriodicalId":50475,"journal":{"name":"European Surgery-Acta Chirurgica Austriaca","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932092/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Surgery-Acta Chirurgica Austriaca","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10353-022-00751-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/3/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 3

Abstract

Introduction: The outbreak of coronavirus disease 2019 (COVID-19) has caused significant delays in oncological care worldwide due to restriction of elective surgery and intensive care unit capacity. It has been hypothesized that COVID-free oncological hubs can provide safer elective cancer surgery compared to COVID hospitals. The primary aim of the present study was to analyze the outcomes of minimally invasive esophagectomy for cancer performed in both hospital settings by the same surgical staff.

Methods: All esophagectomies for cancer performed during the pandemic by a single team were reviewed and data were compared with control patients operated during the preceding year. Screening for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) was performed prior to surgery, and special precautions were taken to mitigate hospital-related transmission of COVID-19 among patients and healthcare workers.

Results: Compared to the prepandemic period, the esophagectomy volume decreased by 64%. Comorbidities, time from onset of symptoms to first visit, waiting time between diagnosis and surgery, operative approach and technique, and the pathological staging were similar. None of the patients tested positive for COVID-19 during in-hospital stay, and esophagectomy was associated with similar outcomes compared to control patients.

Conclusion: Outcomes of minimally invasive esophagectomy for cancer performed in a COVID hospital after implementation of a COVID-free surgical pathway did not differ from those obtained in an oncological hub by the same surgical team.

Abstract Image

查看原文本刊更多论文

微创食管切除术在新冠医院和肿瘤中心治疗癌症:结果不同吗?

导语:2019年冠状病毒病(COVID-19)的爆发，由于选择性手术和重症监护病房容量的限制，导致全球肿瘤护理严重延误。据推测，与新冠医院相比，没有新冠病毒的肿瘤中心可以提供更安全的选择性癌症手术。本研究的主要目的是分析在两家医院由同一手术人员进行的微创食管癌切除术的结果。方法:回顾了在大流行期间由一个团队进行的所有食管癌切除术，并将数据与前一年手术的对照患者进行比较。手术前进行了严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)筛查，并采取了特殊预防措施，以减少COVID-19在患者和医护人员之间的医院相关传播。结果:与大流行前相比，食管切除术体积减少了64%。合并症、从症状出现到首次就诊的时间、诊断到手术的等待时间、手术入路和技术以及病理分期相似。在住院期间，没有一名患者的COVID-19检测呈阳性，与对照组患者相比，食管切除术的结果相似。结论:在COVID医院实施无COVID手术路径后，微创食管癌切除术的结果与同一外科团队在肿瘤中心获得的结果没有差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Surgery-Acta Chirurgica Austriaca 医学-外科

CiteScore

1.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The journal European Surgery – Acta Chirurgica Austriaca focuses on general surgery, endocrine surgery, thoracic surgery, heart and vascular surgery. Special features include new surgical and endoscopic techniques such as minimally invasive surgery, robot surgery, and advances in surgery-related biotechnology and surgical oncology. The journal especially addresses benign and malignant esophageal diseases, i.e. achalasia, gastroesophageal reflux disease, Barrett’s esophagus, and esophageal adenocarcinoma. In keeping with modern healthcare requirements, the journal’s scope includes inter- and multidisciplinary disease management (diagnosis, therapy and surveillance).